|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
5
|
|
pubmed:dateCreated |
2007-9-20
|
|
pubmed:abstractText |
Growth factor overexpression, including epidermal growth factor receptor (EGFR) expression, is common in hepatocellular cancers. Erlotinib is a receptor tyrosine kinase inhibitor with specificity for EGFR. The primary objective of this study was to determine the proportion of hepatocellular carcinoma (HCC) patients treated with erlotinib who were alive and progression-free (PFS) at 16 weeks of continuous treatment.
|
|
pubmed:grant |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
AIM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Sep
|
|
pubmed:issn |
0008-543X
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
1
|
|
pubmed:volume |
110
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
1059-67
|
|
pubmed:dateRevised |
2010-11-18
|
|
pubmed:meshHeading |
pubmed-meshheading:17623837-Adult,
pubmed-meshheading:17623837-Aged,
pubmed-meshheading:17623837-Aged, 80 and over,
pubmed-meshheading:17623837-Carcinoma, Hepatocellular,
pubmed-meshheading:17623837-Diarrhea,
pubmed-meshheading:17623837-Drug Administration Schedule,
pubmed-meshheading:17623837-Exanthema,
pubmed-meshheading:17623837-Fatigue,
pubmed-meshheading:17623837-Female,
pubmed-meshheading:17623837-Humans,
pubmed-meshheading:17623837-Immunohistochemistry,
pubmed-meshheading:17623837-Kaplan-Meier Estimate,
pubmed-meshheading:17623837-Liver Neoplasms,
pubmed-meshheading:17623837-Male,
pubmed-meshheading:17623837-Middle Aged,
pubmed-meshheading:17623837-Protein Kinase Inhibitors,
pubmed-meshheading:17623837-Quinazolines,
pubmed-meshheading:17623837-Receptor, Epidermal Growth Factor,
pubmed-meshheading:17623837-Treatment Outcome
|
|
pubmed:year |
2007
|
|
pubmed:articleTitle |
Phase 2 study of erlotinib in patients with unresectable hepatocellular carcinoma.
|
|
pubmed:affiliation |
Department of Gastrointestinal Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA. methomas@mdanderson.org
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial, Phase II,
Research Support, N.I.H., Extramural
|
